Results 101 to 110 of about 11,568,194 (143)

MRI evaluation of cerebral perivascular spaces predicts amyloid-related imaging abnormalities risk in preclinical Alzheimer's disease. [PDF]

Front Dement
Bigjahan B, Cavallari M, Barisano G.
europepmc   +1 more source

Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab? [PDF]

AJNR Am J Neuroradiol
Rohatgi S, Zhu S, Calle Cadavid E, Ford JN, Kozak BM, Ganem Chagui O, Vejdani-Jahromi M, Griffin HR, Farzaneh H, Huang RY, Seah JC, Omid-Fard N, Gomez-Isla T, Dickson JR, Ramírez Gómez L, Romero JM.   +15 more
europepmc   +1 more source

Risk of amyloid-related imaging abnormalities associated with anticoagulant therapy in patients with Alzheimer's disease treated with anti-amyloid monoclonal antibodies: a systematic review and meta-analysis. [PDF]

J Neurol Neurosurg Psychiatry
Schlemm E, Gauthier S, Magnus T, Thomalla G, Rosa-Neto P, Woo MS.   +5 more
europepmc   +1 more source

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. [PDF]

J Manag Care Spec Pharm
Dangpiaei S, Kamal KM, Shoair OA, Al-Mamun MA.   +3 more
europepmc   +1 more source

Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers. [PDF]

Drugs Aging
Schreiber CP, Kovacik A, Bishop J, Helman J.   +3 more
europepmc   +1 more source

Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study. [PDF]

Lancet Neurol
Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, Johnson DR, Burkett BJ, Lowe VJ, Petersen RC, Dickson DW, Reichard RR, Nguyen AT, Graff-Radford J, Knopman DS, Graff-Radford NR, Murray ME.   +20 more
europepmc   +1 more source

Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data. [PDF]

Alzheimers Res Ther
Noguchi-Shinohara M, Yoshinobu T, Ozaki T, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +10 more
europepmc   +1 more source